State of Melanoma: An Historic Overview of a Field in Transition
- PMID: 33759768
- DOI: 10.1016/j.hoc.2020.09.003
State of Melanoma: An Historic Overview of a Field in Transition
Abstract
The management of melanoma significantly improved within the last 25 years. Chemotherapy was the first approved systemic therapeutic approach and resulted in a median overall of survival less than 1 year, without survival improvement in phase III trials. High-dose interferon α2b and IL-2 were introduced for resectable high-risk and advanced disease, respectively, resulting in improved survival and response rates. The anti-CTLA4 and anti-programmed death 1 monoclonal antibodies along with BRAF/MEK targeted therapies are the dominant therapeutic classes of agent for melanoma. This article provides an historic overview of the evolution of melanoma management.
Keywords: Immunotherapy; Interferon; Interleukin-2; Melanoma; Targeted therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure L. Karapetyan declares no disclosures or conflicts of interest. J.M. Kirkwood Consulting: Amgen, Inc., BMS, Checkmate, Novartis. Research support to institution: Amgen, BMS, Checkmate, Castle Biosciences, Inc., Immunocore LLC, Iovance, Novartis.
Similar articles
-
Historical review of melanoma treatment and outcomes.Clin Dermatol. 2013 Mar-Apr;31(2):141-7. doi: 10.1016/j.clindermatol.2012.08.015. Clin Dermatol. 2013. PMID: 23438377 Review.
-
(Neo)adjuvant systemic therapy for melanoma.Eur J Surg Oncol. 2017 Mar;43(3):534-543. doi: 10.1016/j.ejso.2016.07.001. Epub 2016 Jul 11. Eur J Surg Oncol. 2017. PMID: 27453302 Review.
-
Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis.Am J Clin Dermatol. 2018 Nov;19(Suppl 1):24-30. doi: 10.1007/s40257-018-0379-0. Am J Clin Dermatol. 2018. PMID: 30374897 Free PMC article. Review.
-
State of melanoma: an historic overview of a field in transition.Hematol Oncol Clin North Am. 2014 Jun;28(3):415-35. doi: 10.1016/j.hoc.2014.02.010. Hematol Oncol Clin North Am. 2014. PMID: 24880939 Free PMC article. Review.
-
[Targeted therapies for melanoma].Hautarzt. 2014 Jul;65(7):600-6. doi: 10.1007/s00105-013-2735-6. Hautarzt. 2014. PMID: 24962553 German.
Cited by
-
Empowering standardization of cancer vaccines through ontology: enhanced modeling and data analysis.J Biomed Semantics. 2024 Jun 19;15(1):12. doi: 10.1186/s13326-024-00312-3. J Biomed Semantics. 2024. PMID: 38890666 Free PMC article.
-
Poorer survival outcomes in patients with multiple versus single primary melanoma.Cancer. 2022 Jun 1;128(11):2098-2106. doi: 10.1002/cncr.34169. Epub 2022 Mar 23. Cancer. 2022. PMID: 35319783 Free PMC article.
-
Exogenous Hydrogen Sulfide Induces A375 Melanoma Cell Apoptosis Through Overactivation of the Unfolded Protein Response.Clin Cosmet Investig Dermatol. 2023 Jun 27;16:1641-1651. doi: 10.2147/CCID.S412588. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 37396710 Free PMC article.
-
Extra-Axial Skeletal Metastasis of Malignant Melanoma: Case Report and Literature Review.Cureus. 2022 Feb 11;14(2):e22115. doi: 10.7759/cureus.22115. eCollection 2022 Feb. Cureus. 2022. PMID: 35308763 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials